Tariffs imposed by President Donald Trump’s administration have impacted several realms of healthcare, from drug costs to medical device pressures.
The anesthesia and respiratory device market could be the next to be targeted, according to a May 8 report from Express Healthcare.
Currently, 67% of FDA-cleared anesthesia and respiratory devices are manufactured outside of the U.S., according to the report. That means that costs are likely to rise for anesthesia-related devices.
U.S. tariffs on China have been set at 145%, with 17% of FDA-approved anesthesia devices coming from China.
“Companies facing greater financial risk, such as Respironics, may consider shifting more production to the U.S.,” Aidan Robertson, a medical analyst at GlobalData, told Express. “However, this can lead to significant short-term revenue losses, benefiting competitors with stronger domestic manufacturing operations. As a result, the U.S. anesthesia and respiratory market may see a shift in market share as healthcare providers turn to suppliers better positioned to navigate the tariffs.”
The post Anesthesia device market disrupted by tariffs appeared first on Becker’s ASC.
